GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Telo Genomics Corp (TSXV:TELO) » Definitions » Net Change in Cash

Telo Genomics (TSXV:TELO) Net Change in Cash : C$0.96 Mil (TTM As of Dec. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Telo Genomics Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Telo Genomics's Net Change in Cash for the three months ended in Dec. 2024 was C$1.92 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2024 was C$0.96 Mil.

Telo Genomics Net Change in Cash Historical Data

The historical data trend for Telo Genomics's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telo Genomics Net Change in Cash Chart

Telo Genomics Annual Data
Trend Dec14 Dec15 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.90 2.72 -0.94 -0.02 -1.88

Telo Genomics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.68 -0.61 0.11 -0.47 1.92

Telo Genomics Net Change in Cash Calculation

Telo Genomics's Net Change in Cash for the fiscal year that ended in Jun. 2024 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-2.459+-0.005+0.587+0
=-1.88

Telo Genomics's Net Change in Cash for the quarter that ended in Dec. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-0.406+0+2.326+0
=1.92

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.96 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Telo Genomics Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Telo Genomics's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Telo Genomics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Telo Genomics Corp (TSXV:TELO) » Definitions » Net Change in Cash
Comparable Companies
TSXV:ARC TSXV:AVCR XCNQ:IZO XCNQ:VTAL TSXV:MBI.H XCNQ:BUX XCNQ:SONA TMO DHR XSWX:LONN IDXX A IQV SHSE:603259 MTD NTRA WAT DGX LH XPAR:BIM
Traded in Other Exchanges
TDSGF:USA
Address
101 College Street, Suite 200, MaRS Centre, South Tower, Toronto, ON, CAN, M5G 1L7
Website
https://www.telodx.com
Telo Genomics Corp is a personalized medicine company. The company through its wholly-owned subsidiary is engaged in developing diagnostic and prognostic products that may save lives, improve the quality of life, and reduce the cost of care associated with numerous diseases that display genomic instability. The company has a single operating segment, focused on the development and commercialization of predictive technological products designed to personalize treatment plans for patients who have specific conditions.
Executives
Kristan Joseph Weinberg Senior Officer
William John Meekison Director
Hugh Rogers Director

Telo Genomics Headlines

From GuruFocus

Telomir Pharmaceuticals Announces Breakthrough: Telomir-1 Reverses Calcium Dysregulation, the Hidden Driver of Aging and Disease, in Multiple Human Cell Lines

By ACCESSWIRE • 02-26-2025

UPDATE -- Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

By GlobeNewswire • 03-29-2024

Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.

By Marketwired • 04-16-2024

Telomir Pharmaceuticals Featured in Local ABC Exclusive Showing Positive Outcomes of Proposed Age Reversal Pill in Dogs

By ACCESSWIRE • 08-20-2024

Telomir Pharmaceuticals Achieves Breakthrough in Silver Ion Stabilization, Unlocking a Multi-Billion-Dollar Medical Market

By ACCESSWIRE • 02-21-2025

Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications

By ACCESSWIRE • 09-04-2024

Telomir Pharmaceuticals Announces Significant Reduction of Oxidative Stress in Human Retinal Cell Lines, Advancing Potential Treatment for Age-Related Macular Degeneration (AMD)

By ACCESSWIRE • 02-18-2025

Telomir Pharmaceuticals Added to Membership of Russell 3000 and Russell Microcap Indexes

By Marketwired • 07-02-2024

Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells

By ACCESSWIRE • 03-19-2025

Telomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1

By Marketwired • 05-30-2024